Extracorporeal phototherapy in multiple sclerosis

Neurological Sciences

Volumn 27, Issue 1, 2006, Pages 3-4

  Comi, Giancarlo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; FTY 120; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LAQUINIMOD; MITOXANTRONE; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; EUROPE; EXTRACORPOREAL PHOTOCHEMOTHERAPY; GRAFT VERSUS HOST REACTION; HUMAN; INDIVIDUALIZATION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NORTH AMERICA; NOTE; PHOTOCHEMOTHERAPY; REGULATORY T LYMPHOCYTE; SCLERODERMA; SKIN LYMPHOMA; T CELL LYMPHOMA; TH2 CELL; TREATMENT RESPONSE; EDITORIAL; IMMUNOLOGY; PATIENT SELECTION; PUVA; RECURRENT DISEASE; STATISTICS; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS; PATIENT SELECTION; PHOTOPHERESIS; RECURRENCE; TREATMENT OUTCOME;

EID: 33745256446     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0556-4     Document Type: Note

References (13)

1. Comi G (2005) Optimisation of immunomodulatory therapies. Neurol Sci 26[Suppl. 1]:15-17
2. CHAMPIONS Study Group (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:1-7
3. Comi G (2000) Why treat early multiple sclerosis patients? Curr Opin Neurol 13:235-240
4. Kappos L, Polman C, Freedman MS et al (2005) Betaferon, in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Clinical results. Mult Scler 11[Suppl. 1]:10
5. Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904
6. Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 357:1576-1582
7. Foss FM (2006) New insights into the mechanism of action of extracorporeal phototherapy. Transfusion 46:6-8
8. Seaton ED, Szydlo RM, Kanfer E et al (2003) Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 102:1217-1223
9. Berger CL, Longley J, Hanlon D et al (2001) The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann NY Acad Sci 941:106-122
10. Rostami AM, Sater RA, Bird SJ et al (1999). A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler 5:198-203
11. Poehlau D, Rieks M, Postert T (1997) Photopheresis - a possible treatment of multiple sclerosis? Report of two cases. J Clin Apheresis 12:154-155
12. Besnier DP, Chabannes D, Mussini JM et al (2002) Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed 18:36-41
13. Cavaletti G, Perseghin P, Dassi M et al (2006) Extracorporeal photochemotherapy: A safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurol Sci 27:24-32